NICE Ltd.

NICE | NASDAQ

Price Alert Chart Builder DCF Calculator

$114.68

+$0.92 (+0.81%)

Nov 2, 2026, 11:18 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.81%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

63.4

+10.6 pts

Fundamentals Strong

Market Sentiment Neutral

Moat Narrow

Sector Rank #203/819 (Top 25%)

Full Analysis

Key Statistics

Market Data

Market Cap $6.7B

1D Range

113.51 115.43

52W Range

83.15 135.54

Valuation (TTM)

PE 16.49

PB 1.84

EV/EBITDA 7.79

Valuation (NTM)

Forward PE 8.72

Forward PEG -1.82

Price Target $124.20

Cash Flow

FCF Yield 8.7%

SBC Adj. FCF Yield 7.3%

SBC Impact -16.6%

Margins

Gross Margin 65.1%

Operating Margin 18.6%

FCF Margin 19.7%

Growth (CAGR)

Revenue 3Y | 5Y 10.6% | 11.9%

Dil EPS 3Y | 5Y 14.5% | 17.7%

FCF 3Y | 5Y 11.1% | 5.6%

Returns

ROA 8.4%

ROE 11.3%

ROIC 9.8%

Financial Health

Net Cash

$344.44M

Current Ratio 1.33

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

NICE Ltd., together with its subsidiaries, provides AI-powered cloud platforms for customer engagement, and financial crime and compliance in the United States, Europe, the Middle East, Africa, and th...

Sector Technology

Industry Software - Application

Employees 9,626

IPO Date Jan 25, 1996

Website www.nice.com

Fiscal Year January - December

Full Company Profile

Latest News

3 days ago · zacks.com

Ahead of Nice (NICE) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Get a deeper insight into the potential performance of Nice (NICE) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

6 days ago · seekingalpha.com

Parnassus Value Equity Fund Q3 2026 Portfolio Review

Parnassus Value Equity Fund (Investor Shares) returned -1.38% (net of fees) for the quarter, underperforming the Russell 1000 Value Index's 2.61%. Top contributors include Thermo Fisher, CME Group, NICE, Willis Towers Watson and Verizon. Bottom contributors include Cummins, Applied Materials, Brookfield Renewable, Home Depot and AstraZeneca.

6 days ago · zacks.com

Nice (NICE) Beats Stock Market Upswing: What Investors Need to Know

Nice (NICE) concluded the recent trading session at $122.41, signifying a +1.02% move from its prior day's close.

9 days ago · gurufocus.com

Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer

Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca's IMFINZIÂ (durvalumab) in combination with neoadjuvant enfortu

12 days ago · zacks.com

Wall Street Analysts See Nice (NICE) as a Buy: Should You Invest?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?